Study Exploring Safety, Pharmacokinetic and Pharmacodynamic of BN82451 in Male Huntington’s Disease Patients
- 26 Juin 2024 - 1 mn de lecture
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of BN82451B versus placebo after oral administration twice daily (bid) for 28 days in patients with Huntington’s Disease (HD).
26 Juin 2024
1 mn de lecture
Which is the Best Dose of Dysport in Helping With Hip Pain for Children With Cerebral Palsy?
26 Juin 2024
1 mn de lecture
Study to Assess Impact of Dysport Injections Early After Stroke on Upper Limb Spasticity Progression
26 Juin 2024
1 mn de lecture
Efficacy and Safety Study of Botulinum Toxin Type-A (Dysport®) in Continent Female Subjects Suffering From Idiopathic Overactive Bladder
26 Juin 2024
1 mn de lecture
Dysport® Pediatric Lower Limb Spasticity Follow-on Study
26 Juin 2024
1 mn de lecture
Dysport® Adult Lower Limb Spasticity Follow-on Study
26 Juin 2024
1 mn de lecture
Dysport® Pediatric Lower Limb Spasticity Study
26 Juin 2024
1 mn de lecture
Efficacy and Safety of Botulinum Toxin Type A Haemagglutinin Complex Next Generation (BTX-A-HAC NG) in Glabellar Lines
26 Juin 2024
1 mn de lecture
Dysport® Adult Lower Limb Spasticity Study
26 Juin 2024
1 mn de lecture
Efficacy and Safety of Clostridium Botulinum Toxin Type A to Improve Appearance of Moderate to Severe Glabellar Lines
26 Juin 2024
1 mn de lecture